Division of Hematology, Oncology and Transplantation
-
Committed to providing the highest quality care based on cutting edge research to patients with cancer or non-malignant hematologic diseases such as sickle cell disease
-
Dedicated to advancing research on the biological underpinnings of cancer, stem cell biology, sickle cell anemia, endothelial cell biology, and tumor immunology
-
Over 50 full-time academic investigators involved in interdisciplinary research and patient care are devoted to training the next generation of academic leaders
Announcements
John Belcher, PhD, received a small grant from Mitobridge, Inc., a biopharmaceutical company developing small molecule therapeutics. A small molecule licensed by Mitobridge has been found to induce heme oxygenase-1, a cytoprotective protein that is depleted in sickle cell disease. Dr. Belcher and his co-investigator Dr. Greg Vercellotti will conduct preclinical studies to determine whether this novel therapeutic is safe and biologically active in a transgenic mouse model of sickle cell disease. August 2018
John Belcher, PhD, received a half-million-dollar grant from CSL Bering, a global leader in the plasma protein biotherapeutics industry. With the support of this grant, Dr. Belcher and his co-investigator Dr. Greg Vercellotti will conduct preclinical studies to evaluate the pharmacodynamics and pharmacokinetics of purified human hemopexin in a transgenic mouse model of sickle cell disease. August 2018